Vascular cognitive impairment
| Autor: | J. V. Bowler |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Dopamine Agents
CADASIL Disease Neuropsychological Tests Bioinformatics 0302 clinical medicine Secondary Prevention 030212 general & internal medicine Cognitive decline Donepezil Stroke Randomized Controlled Trials as Topic Aged 80 and over Cognitive disorder Memantine Cognition Prognosis Magnetic Resonance Imaging Psychiatry and Mental health Treatment Outcome Cardiology and Cardiovascular Medicine Psychology medicine.drug medicine.medical_specialty 03 medical and health sciences Galantamine Journal Article medicine Dementia Humans Intensive care medicine Psychiatry Vascular dementia Antihypertensive Agents Aged Advanced and Specialized Nursing business.industry Vascular disease Dementia Vascular medicine.disease Binswanger's disease Cerebrovascular Disorders Cholinergic Surgery Neurology (clinical) Cholinesterase Inhibitors business Cognition Disorders 030217 neurology & neurosurgery |
| Zdroj: | Stroke. 35(2) |
| ISSN: | 1524-4628 |
| Popis: | Developments in the field of vascular cognitive impairment over the past year have been evolutionary rather than revolutionary and spread across many aspects. However, even evolutionary changes may be radical, and it is in 3 particular aspects—those of treatment, prevention, and the evaluation of white matter disease—that evolution has been at its most rapid. Since 2002, 5 large, randomized studies of the symptomatic treatment of probable and possible vascular dementia have been published. This is a radical development, and these few studies exceed everything that has been published before. These comprise 2 studies of the anticholinesterase donepezil in vascular dementia,1,2 2 studies of the NMDA receptor antagonist memantine in mild to moderate vascular dementia,3,4 and a study of the anticholinesterase galantamine in “probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease.”5 While these findings are exciting and represent new developments, there are a number of cautions. The first is the relatively modest benefits seen in all these trials. For the anticholinesterases, the benefit on the ADAS-Cog6 amounts to about 3 points and to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|